FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:940-942 September 3, 2009 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

On July 10, 2009, after an 18-month review, the Food and Drug Administration (FDA) approved the thienopyridine prasugrel for use in patients with unstable angina or myocardial infarction who undergo percutaneous coronary intervention (PCI). The new drug is the latest addition to a class of agents that inhibit the platelet adenosine diphosphate (ADP) receptor, preventing initial platelet activation and consequent platelet aggregation — a mechanism that has represented a major advance in the treatment of atherothrombotic diseases.¹ Indeed, the use of the thienopyridine ticlopidine in combination with aspirin to inhibit platelet aggregation facilitated the widespread use of coronary-artery stenting. Because . . . [Full Text of this Article]

Source Information

From the Department of Cardiology at the Veterans Affairs (VA) Boston Healthcare System and the integrated interventional cardiovascular program at Brigham and Women's Hospital and the VA Boston Healthcare System — both in Boston.

This article (10.1056/NEJMp0806848) was published on July 15, 2009, at NEJM.org.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.